International Journal of Colorectal Disease

, Volume 28, Issue 3, pp 295–304 | Cite as

IBS and the role of otilonium bromide

  • Guy Boeckxstaens
  • Enrico S. Corazziari
  • Fermín Mearin
  • Jan Tack



Awareness of the seriousness of irritable bowel disorder (IBS) remains low among clinicians. In this review, we summarize the current knowledge of IBS and highlight the major personal, economic, and social burden of the disease, and the importance of adequate treatment of what is still often viewed as a trivial disorder. In fact, IBS is a major reason for referral.


It is crucial that the varied pathophysiologies of this complex heterogeneous disease are understood in order to be able to treat both the presenting symptoms (pain, bloating, flatulence, abnormal defecation, diarrhea, constipation) and the underlying disorder effectively. Low-grade inflammatory and immune activation has been observed, but the precise triggers and mechanisms, and the relevance to symptom generation, remain to be established.


IBS patients require different treatment strategies according to the pattern, severity, frequency, and symptoms. While initial therapy traditionally targets the most bothersome symptom, long-term therapy aims at maintaining symptom control and preventing recurrence. In addition to dietary/lifestyle interventions and psychosocial strategies, a wide range of pharmacologic therapies are approved for use in IBS depending on the symptoms reported. Musculotropic spasmolytics, which act directly on intestinal smooth muscle contractility, such as otilonium bromide, are effective, particularly in the relief of abdominal pain and bloating, and are well tolerated in IBS.

The OBIS trial

The recent large placebo-controlled Otilonium Bromide in Irritable Bowel Syndrome study demonstrated the superiority of otilonium bromide versus placebo not only in the reduction of pain and bloating, but also in protection from relapse due to the long-lasting effect.


Otilonium bromide Irritable bowel disorder Spasmolytics Irritable bowel syndrome 


  1. 1.
    Mearin F, Badia X, Balboa A, Baro E, Caldwell E, Cucala M, Diaz-Rubio M, Fueyo A, Ponce J, Roset M, Talley NJ (2001) Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol 36:1155–1161PubMedCrossRefGoogle Scholar
  2. 2.
    Saito YA, Schoenfeld P, Locke GR (2002) The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 97:1910–1915PubMedGoogle Scholar
  3. 3.
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480–1491PubMedCrossRefGoogle Scholar
  4. 4.
    Sperber AD, Shvartzman P, Friger M, Fich A (2007) A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the ‘true’ prevalence of irritable bowel syndrome? Eur J Gastroenterol Hepatol 19:441–447PubMedCrossRefGoogle Scholar
  5. 5.
    Choung RS, Locke GR (2011) Epidemiology of IBS. Gastroenterol Clin North Am 40:1–10PubMedCrossRefGoogle Scholar
  6. 6.
    Longstreth GF, Wolde-Tsadik G (1993) Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates. Dig Dis Sci 38:1581–1589PubMedCrossRefGoogle Scholar
  7. 7.
    Russo MW, Gaynes BN, Drossman DA (1999) A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterol 29:339–343PubMedCrossRefGoogle Scholar
  8. 8.
    Drossman DA, Thompson WG (1992) The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med 116:1009–1016PubMedGoogle Scholar
  9. 9.
    Lembo A, Ameen VZ, Drossman DA (2005) Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 3(8):717–725PubMedCrossRefGoogle Scholar
  10. 10.
    Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R (2002) The burden of selected digestive diseases in the United States. Gastroenterology 122:1500–1511PubMedCrossRefGoogle Scholar
  11. 11.
    Hollowell J, Lundgren A, Johansson S (2002) Irritable bowel syndrome: patterns of ambulatory health care and resource use in the United States, 1993–1997. Dig Dis Sci 47:1115–1121PubMedCrossRefGoogle Scholar
  12. 12.
    Inadomi JM, Fennerty MB, Bjorkman D (2003) Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 18:671–682PubMedCrossRefGoogle Scholar
  13. 13.
    Hillila MT, Farkkila NJ, Farkkila MA (2010) Societal costs for irritable bowel syndrome—a population based study. Scand J Gastroenterol 45:582–591PubMedCrossRefGoogle Scholar
  14. 14.
    Johansson PA, Farup PG, Bracco A, Vandvik PO (2010) How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice. BMC Gastroenterol 10:31PubMedCrossRefGoogle Scholar
  15. 15.
    Longstreth GF, Yao JF (2004) Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 126:1665–1673PubMedCrossRefGoogle Scholar
  16. 16.
    Chang JY, Locke GR, McNally MA, Halder SL, Schleck CD, Zinsmeister AR, Talley NJ (2010) Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol 105:822–832PubMedCrossRefGoogle Scholar
  17. 17.
    Norgaard M, Farkas DK, Pedersen L, Erichsen R, de la Cour ZD, Gregersen H, Sorensen HT (2011) Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study. Br J Cancer 104:1202–1206PubMedCrossRefGoogle Scholar
  18. 18.
    Spiegel B, Schoenfeld P, Naliboff B (2007) Systematic review: the prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome. Aliment Pharmacol Ther 26:183–193PubMedCrossRefGoogle Scholar
  19. 19.
    Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ (2004) Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 53:666–672PubMedCrossRefGoogle Scholar
  20. 20.
    Delvaux M (2002) Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 51(Suppl 1):i67–i71PubMedCrossRefGoogle Scholar
  21. 21.
    Camilleri M (2009) Genetics and irritable bowel syndrome: from genomics to intermediate phenotype and pharmacogenetics. Dig Dis Sci 54:2318–2324PubMedCrossRefGoogle Scholar
  22. 22.
    Ohman L, Simren M (2010) Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 7:163–173PubMedCrossRefGoogle Scholar
  23. 23.
    Camilleri M (1999) Motor function in irritable bowel syndrome. Can J Gastroenterol 13(Suppl A):8A–11APubMedGoogle Scholar
  24. 24.
    Barbara G, Stanghellini V (2009) Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut 58:1571–1575PubMedCrossRefGoogle Scholar
  25. 25.
    Azpiroz F (2005) Intestinal gas dynamics: mechanisms and clinical relevance. Gut 54:893–895PubMedCrossRefGoogle Scholar
  26. 26.
    Kuiken SD, Lindeboom R, Tytgat GN, Boeckxstaens GE (2005) Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 22:157–164PubMedCrossRefGoogle Scholar
  27. 27.
    Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA (1995) Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 109:40–52PubMedCrossRefGoogle Scholar
  28. 28.
    Lembo T, Munakata J, Mertz H, Niazi N, Kodner A, Nikas V, Mayer EA (1994) Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome. Gastroenterology 107:1686–1696PubMedGoogle Scholar
  29. 29.
    Elsenbruch S, Rosenberger C, Enck P, Forsting M, Schedlowski M, Gizewski ER (2010) Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study. Gut 59:489–495PubMedCrossRefGoogle Scholar
  30. 30.
    Blankstein U, Chen J, Diamant NE, Davis KD (2010) Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. Gastroenterology 138:1783–1789PubMedCrossRefGoogle Scholar
  31. 31.
    Seminowicz DA, Labus JS, Bueller JA, Tillisch K, Naliboff BD, Bushnell MC, Mayer EA (2010) Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology 139:48–57.e2PubMedCrossRefGoogle Scholar
  32. 32.
    Elsenbruch S (2011) Abdominal pain in irritable bowel syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun 25:386–394PubMedCrossRefGoogle Scholar
  33. 33.
    Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM (2003) Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 52:523–526PubMedCrossRefGoogle Scholar
  34. 34.
    Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR (2000) Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47:804–811PubMedCrossRefGoogle Scholar
  35. 35.
    Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martinez C, Casellas F, Saperas E, Malagelada JR (2007) Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 56:203–209PubMedCrossRefGoogle Scholar
  36. 36.
    Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett NW, Grundy D, Corinaldesi R (2007) Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 132:26–37PubMedCrossRefGoogle Scholar
  37. 37.
    Bueno L, Fioramonti J (2002) Visceral perception: inflammatory and non-inflammatory mediators. Gut 51(Suppl 1):i19–i23PubMedCrossRefGoogle Scholar
  38. 38.
    Azpiroz F, Bouin M, Camilleri M, Mayer EA, Poitras P, Serra J, Spiller RC (2007) Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 19:62–88PubMedCrossRefGoogle Scholar
  39. 39.
    Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N (2007) Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 117:636–647PubMedCrossRefGoogle Scholar
  40. 40.
    Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE (2010) The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 59:1213–1221PubMedCrossRefGoogle Scholar
  41. 41.
    Soderholm JD, Yang PC, Ceponis P, Vohra A, Riddell R, Sherman PM, Perdue MH (2002) Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 123:1099–1108PubMedCrossRefGoogle Scholar
  42. 42.
    Zhou Q, Souba WW, Croce CM, Verne GN (2010) MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 59:775–784PubMedCrossRefGoogle Scholar
  43. 43.
    Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, Neunlist M (2009) Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58:196–201PubMedCrossRefGoogle Scholar
  44. 44.
    Gecse K, Roka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztoczy A, Izbeki F, Fioramonti J, Wittmann T, Bueno L (2008) Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 57:591–599PubMedCrossRefGoogle Scholar
  45. 45.
    Lee KJ, Tack J (2010) Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil 22:493–498PubMedCrossRefGoogle Scholar
  46. 46.
    Thomas KB (1987) General practice consultations: is there any point in being positive? Br Med J 294:1200–1202CrossRefGoogle Scholar
  47. 47.
    Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS (2009) The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 104:1033–1049, quiz 1050PubMedCrossRefGoogle Scholar
  48. 48.
    Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P (2009) A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 9:15PubMedCrossRefGoogle Scholar
  49. 49.
    Cadau G, Pallotta D, Badiali D, Corazziari E (1998) L’impiego degli antidepressivi triciclici a basso dosaggio nel trattamento dei disturbi funzionali del tratto gastrointestinal superior ed inferiore. Neurogastroenterologica 4:16–20Google Scholar
  50. 50.
    Drossman DA, Camilleri M, Mayer EA, Whitehead WE (2002) AGA technical review on irritable bowel syndrome. Gastroenterology 123:2108–2131PubMedCrossRefGoogle Scholar
  51. 51.
    Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P (2009) Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 58:367–378PubMedCrossRefGoogle Scholar
  52. 52.
    Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364:22–32PubMedCrossRefGoogle Scholar
  53. 53.
    Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG (2007) A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 102:1709–1719PubMedCrossRefGoogle Scholar
  54. 54.
    Olden KW, Crowell MD (2005) Cilansetron. Drugs Today (Barc) 41:661–666CrossRefGoogle Scholar
  55. 55.
    Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, Schlumberger A, Jakob S, Whorwell PJ (2009) Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29:104–114PubMedCrossRefGoogle Scholar
  56. 56.
    Sakai T, Makino H, Ishikawa E, Oishi K, Kushiro A (2011) Fermented milk containing Lactobacillus casei strain Shirota reduces incidence of hard or lumpy stools in healthy population. Int J Food Sci Nutr 62:423–430PubMedCrossRefGoogle Scholar
  57. 57.
    Corazziari E, Badiali D, Bazzocchi G, Bassotti G, Roselli P, Mastropaolo G, Luca MG, Galeazzi R, Peruzzi E (2000) Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 46:522–526PubMedCrossRefGoogle Scholar
  58. 58.
    Ford AC, Suares NC (2011) Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 60:209–218PubMedCrossRefGoogle Scholar
  59. 59.
    Drossman DA, Chey W, Panas R, Wahle A, Scott C, Ueno R (2007) Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two twelve-week, randomized, placebo-controlled, double-blind trials. Gastroenterology & Hepatology 132:2586–2587Google Scholar
  60. 60.
    American College of Gastroenterology Functional Gastrointestinal Disorders Task Force (2002) Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97:S1–S5Google Scholar
  61. 61.
    Whorwell PJ, Prior A, Colgan SM (1987) Hypnotherapy in severe irritable bowel syndrome: further experience. Gut 28:423–425PubMedCrossRefGoogle Scholar
  62. 62.
    Toner BB (2005) Cognitive-behavioral treatment of irritable bowel syndrome. CNS Spectr 10:883–890PubMedGoogle Scholar
  63. 63.
    Madisch A, Holtmann G, Plein K, Hotz J (2004) Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 19:271–279PubMedCrossRefGoogle Scholar
  64. 64.
    Leung WK, Wu JC, Liang SM, Chan LS, Chan FK, Xie H, Fung SS, Hui AJ, Wong VW, Che CT, Sung JJ (2006) Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial. Am J Gastroenterol 101:1574–1580PubMedCrossRefGoogle Scholar
  65. 65.
    Scarpignato C, Pelosini I (1999) Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Can J Gastroenterol 13(Suppl A):50A–65APubMedGoogle Scholar
  66. 66.
    Tack J, Fried M, Houghton LA, Spicak J, Fisher G (2006) Systematic review: the efficacy of treatments for irritable bowel syndrome—a European perspective. Aliment Pharmacol Ther 24:183–205PubMedCrossRefGoogle Scholar
  67. 67.
    Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N (2002) Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97:S7–S26PubMedGoogle Scholar
  68. 68.
    Wheatley D (1976) Irritable colon syndrome treated with an antispasmodic drug. Practitioner 217:276–280Google Scholar
  69. 69.
    Page JG, Dirnberger GM (1981) Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 3:153–156PubMedCrossRefGoogle Scholar
  70. 70.
    Ritchie JA, Truelove SC (1979) Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J 1:376–378PubMedCrossRefGoogle Scholar
  71. 71.
    Dobrilla G, Imbimbo BP, Piazzi L, Bensi G (1990) Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut 31:355–358PubMedCrossRefGoogle Scholar
  72. 72.
    Centonze V, Imbimbo BP, Campanozzi F, Attolini E, Daniotti S, Albano O (1988) Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol 83:1262–1266PubMedGoogle Scholar
  73. 73.
    Piai G, Visconti M, Imbimbo BP (1987) Long-term treatment of irritable bowel syndrome with cimetropium bromide, a new antimuscarinic compound. Curr Ther Res 41:967–977Google Scholar
  74. 74.
    Kruis W, Weinzierl M, Schussler P, Holl J (1986) Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion 34:196–201PubMedCrossRefGoogle Scholar
  75. 75.
    Baldi F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G, Corazziari E, Badiali G, Pescatori M, Anastasio G et al (1991) Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. Ital J Gastroenterol 23:60–63PubMedGoogle Scholar
  76. 76.
    Battaglia G, Morselli-Labate AM, Camarri E, Francavilla A, De Marco F, Mastropaolo G, Naccarato R (1998) Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 12:1003–1010PubMedCrossRefGoogle Scholar
  77. 77.
    Awad R, Dibildox M, Ortiz F (1995) Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial. Acta Gastroenterol Latinoam 25:137–144PubMedGoogle Scholar
  78. 78.
    Gilvarry J, Kenny A, Fielding JF (1989) The non-effect of pirenzepine in dietary resistant irritable bowel syndrome. Ir J Med Sci 158:262PubMedCrossRefGoogle Scholar
  79. 79.
    Ghidini O, Saponati G, Intrieri L (1986) Single drug treatment for irritable colon: rociverine versus trimebutine maleate. Curr Ther Res 39:541–548Google Scholar
  80. 80.
    Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ (2006) Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 130:1538–1551PubMedCrossRefGoogle Scholar
  81. 81.
    Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N (2005) Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev:CD003460Google Scholar
  82. 82.
    Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL (2004) Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 20:1253–1269PubMedCrossRefGoogle Scholar
  83. 83.
    Poynard T, Regimbeau C, Benhamou Y (2001) Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 15:355–361PubMedCrossRefGoogle Scholar
  84. 84.
    Poynard T, Naveau S, Mory B, Chaput JC (1994) Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 8:499–510PubMedCrossRefGoogle Scholar
  85. 85.
    Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P (2008) Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337:a2313PubMedCrossRefGoogle Scholar
  86. 86.
    Sutton JA, Kilminster SG, Mould GP (1997) The clinical pharmacology of single doses of otilonium bromide in healthy volunteers. Eur J Clin Pharmacol 52:365–369PubMedCrossRefGoogle Scholar
  87. 87.
    Evangelista S, Cochet P, Bromet N, Criscuoli M, Maggi CA (2000) A distribution study with (14)C-otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration. Drug Metab Dispos 28:643–647PubMedGoogle Scholar
  88. 88.
    Evangelista S (1999) Otilonium bromide: a selective spasmolytic for the gastrointestinal tract. J Int Med Res 27:207–222PubMedGoogle Scholar
  89. 89.
    Maggi CA, Manzini S, Meli A (1983) Octylonium bromide: a smooth muscle relaxant which interferes with calcium ions mobilization. Arch Int Pharmacodyn Ther 264:305–323PubMedGoogle Scholar
  90. 90.
    Santicioli P, Zagorodnyuk V, Renzetti AR, Maggi CA (1999) Antimuscarinic, calcium channel blocker and tachykinin NK2 receptor antagonist actions of otilonium bromide in the circular muscle of guinea-pig colon. Naunyn Schmiedebergs Arch Pharmacol 359:420–427PubMedCrossRefGoogle Scholar
  91. 91.
    Strege PR, Evangelista S, Lyford GL, Sarr MG, Farrugia G (2004) Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle. Neurogastroenterol Motil 16:167–173PubMedCrossRefGoogle Scholar
  92. 92.
    Strege PR, Sha L, Beyder A, Bernard CE, Perez-Reyes E, Evangelista S, Gibbons SJ, Szurszewski JH, Farrugia G (2010) T-type Ca(2+) channel modulation by otilonium bromide. Am J Physiol Gastrointest Liver Physiol 298:G706–G713PubMedCrossRefGoogle Scholar
  93. 93.
    Gallego D, Auli M, Aleu J, Martínez E, Rofes L, Marti-Ragué J, Jiménez M, Clavé P (2010) Effect of otilonium bromide on contractile patterns in the human sigmoid colon. Neurogastroenterol Motil 22:e180–e191PubMedCrossRefGoogle Scholar
  94. 94.
    Glende M, Morselli-Labate AM, Battaglia G, Evangelista S (2002) Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol 14:1331–1338PubMedCrossRefGoogle Scholar
  95. 95.
    Clavé P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, Tack J (2011) Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 34:432–442PubMedCrossRefGoogle Scholar
  96. 96.
    Evangelista S (2012) Benefits from long-term treatment in irritable bowel syndrome. Gastroenterol Res Pract 2012:936–960Google Scholar
  97. 97.
    Simrén M (2009) Bloating and abdominal distention: not so poorly understood anymore! Gastroenterology 136(5):1487–1490PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Guy Boeckxstaens
    • 1
  • Enrico S. Corazziari
    • 2
  • Fermín Mearin
    • 3
  • Jan Tack
    • 1
  1. 1.Department of Gastroenterology, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospital LeuvenCatholic University of LeuvenLeuvenBelgium
  2. 2.Department of Internal Medicine and Medical SpecialtiesUniversity La SapienzaRomeItaly
  3. 3.Institute of Functional and Motor Digestive DisordersCentro Medico TeknonBarcelonaSpain

Personalised recommendations